Biostock interviews Chordate Medical’s CEO Anders Weilandt about the International Headache Congress in Seoul, where the results from the migraine study will be presented, and about the manuscript for a scientific article that has now been submitted.
“It is a much-awaited achievement that now, after thorough analysis and writing process by the authors, can be ticked off as delivered. The data material is extensive and in many parts very interesting. As I understand it, there has been some work in choosing what to include in this first article. It is not unlikely that further analysis may result in several articles on aspects other than those presented in this article. Overall, I am very pleased good that the article has been produced – it will provide good support for our marketing work when the article is approved for publication”, says Anders Weilandt to Biostock.
